There are several studies evaluating the functioning in patients with schizophrenia. Nowadays, there are new tools and therapeutic alternatives to be considered.

Our hypothesis is administration of Depot antipsychotic improve patient adherence to treatment which reflect better social and personal performance, higher satisfaction with medication and less severity of the mental illness.

Sample of 68 patients with schizophrenia: 32 with Depot and 36 with oral antipsychotic.Scales: PSP assesses global function in terms of four functional domains: work/study, personal/social relationship, self care and disturbing/aggressive behavior. Other scales applied: CGI and MSQ.

PSP: Self care (t (67)=6.092,Pa=0.01),Personal Relationships (t(67)=3.368,Pa=0.05), Social Relationship(t(67)=5.0167,Pa=0.01) and disturbing behavior(t(67)=1.263,Pa>0.05).

Better response to the four areas studied in patients treated with Depot vs. patients treated with oral medication.The Global score of PSP in oral medication group was 68 which means barriers indentified by anyone but do not interfere with the role of the subject. and in the group of Depot the global score was 78 that mean mild difficulties indentified by relatives or close people to patient.